We are building the iron products of the future
Bio Vitos Pharma combines deep scientific expertise with a proven ability to build and scale successful companies internationally. We are driven by the vision to eliminate the suffering caused by iron deficiency through side-effect-very-low treatments.
Our vision and strategy
Global leader in iron succinate therapies
Bio Vitos Pharma is a Swedish life science company in a transformative phase. By focusing on a unique, patented platform of iron succinate, we address unmet medical needs in heart failure and mental health. Our strategy is based on rapid clinical validation, regulatory approvals via EFSA and strong international expansion.
Senior executives
Helge Trettoe Olsen, Chairman of the Board
Background: Seasoned serial entrepreneur with over 20 years of experience scaling companies.
Track record: Has led several successful IPOs, including on Nasdaq Stockholm.
Robert Simmons, Board Member & Marketing Manager
Background: 20+ years in life sciences, digital health and biotech.
Expertise: Has led investments totaling $235 million and completed nine successful exits.
Dr. Sven Rohmann, CEO
Background: MD, PhD and MBA with over 35 years of leadership experience in global bio-pharma.
Track record: Former CEO of Ganymed Pharmaceuticals AG, which was sold to Astellas for EUR 1.4 billion. Experience in leading successful clinical development programs and creating significant value for investors.
Vetenskapligt råd
Professor Fredrik Nyström
Professor of Internal Medicine and Endocrinology at Linköping University. Specialist in metabolic health with over 150 scientific publications. Leads the company’s clinical programs and regulatory studies.
Our history
2010–2017
Founded in Sweden with a focus on medical technology and diagnostics to eliminate hemolysis.
2021–2023
Strategic restructuring towards drug development and acquisition of rights around ferrous succinate.
2024–2025
Intensification of clinical studies and preparations for international expansion.
2026
Focus on EFSA approval and planned listing on the US stock exchange.
Contact details
Head office: Kungsgatan 9, 111 43 Stockholm, Sweden
Email: [email protected]